Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G... see more

Recent & Breaking News (GREY:SRNE)

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sorrento Therapeutics, Inc. (SRNE) on Behalf of Investors

Business Wire May 27, 2020

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire May 27, 2020

SORRENTO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Sorrento Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire May 27, 2020

SRNE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Sorrento Therapeutics, Inc and Encourages Investors to Contact the Firm

ACCESSWIRE IA May 27, 2020

SRNE INVESTOR ALERT: Kirby McInerney LLP Announces That it has Filed a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors to Contact the Firm Before July 27

GlobeNewswire May 26, 2020

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sorrento Therapeutics, Inc.

Newsfile May 26, 2020

Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis

GlobeNewswire May 26, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE

ACCESSWIRE IA May 25, 2020

SORRENTO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sorrento Therapeutics, Inc. To Contact The Firm

Newsfile May 23, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE

GlobeNewswire May 22, 2020

Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer

GlobeNewswire May 21, 2020

STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies

PR Newswire May 15, 2020

Sorrento And Mount Sinai Health System To Jointly Develop COVI-SHIELD(TM) Antibody Therapy Targeting SARS-CoV-2 Infection (COVID-19)

PR Newswire May 8, 2020

SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS

GlobeNewswire April 2, 2020

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

GlobeNewswire March 31, 2020

Sorrento Launches Novel I-Cell(TM) COVID-19 Cellular Vaccine Program

GlobeNewswire March 25, 2020

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB(TM) TO POTENTIALLY TREAT COVID-19

GlobeNewswire March 24, 2020

SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19

GlobeNewswire March 23, 2020

SORRENTO DEVELOPS STI-4398 (COVIDTRAP(TM) PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

GlobeNewswire March 20, 2020

Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial

GlobeNewswire February 27, 2020